leisure time -WSS

leisure time

author：entertainment 2025-09-02 22:24:58 - browse：9523

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Chamber of Commerce, DOJ clash in court over drug prices

focus

WSS

White House Covid adviser calls on docs to combat misinformation

What do new weight loss drugs mean for bariatric surgery?

AstraZeneca challenges Medicare drug negotiation program

What happened to the House vote on health price transparency?

In science, is the line between industry and academia shifting?

Departing Stanford president retracts two papers

entertainment

leisure time

Wikipedia

Bright Health sells Medicare Advantage business to Molina

The unintended consequences of overturning Roe v. Wade

Drug repurposing or repositioning? The language matters

How Long Island became the ‘eugenics capital of the world’

Jerome Adams on the need for new antivirals for Covid

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Activists slam private health insurers over coverage restrictions

Akili changes sales model for its ADHD video game treatment

DIEP, the 'gold standard' of breast reconstruction, is under threat

What AAP's gender

knowledge

How to make Best Hospitals ratings actually useful for patients

The struggle to figure out which patients 'deserve' Wegovy

Patients, doctors press FTC to beef up hospital merger scrutiny

How Long Island became the ‘eugenics capital of the world’

PBMs drew scrutiny in House hearing — and so did pharma

Neuroscience startup Neumora files for IPO

focus

knowledge

entertainment

entertainment